Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Placebo 40 mg

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,920 result(s) found for: Placebo 40 mg. Displaying page 67 of 196.
    «« First « Previous 63  64  65  66  67  68  69  70  71  Next» Last»»
    EudraCT Number: 2007-001097-90 Sponsor Protocol Number: 11915A Start Date*: 2008-09-23
    Sponsor Name:H. Lundbeck A/S
    Full Title: A one-year multinational, multi-centre, randomised, double-blind, parallel-group, fixed-dose, bifeprunox study combining a 12 week placebo-controlled, quetiapine-referenced phase with a 12-month qu...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    10.0 10039626 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001353-16 Sponsor Protocol Number: BAY63-2521/16277 Start Date*: 2015-04-17
    Sponsor Name:Bayer AG
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
    Medical condition: diffuse cutaneous systemic sclerosis (dcSSc)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10012977 Diffuse systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) BE (Completed) ES (Completed) CZ (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003066-32 Sponsor Protocol Number: CQBX258X2201 Start Date*: 2012-02-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized double-blind multiple-dose placebo-controlled trial to establish the efficacy of QBX258 (combination of VAK694 and QAX576) in asthma that is inadequately controlled with inhaled cortic...
    Medical condition: Patients with asthma that are inadequately controlled with inhaled corticosteroids and long acting beta agonists
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10049106 Asthma chronic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002536-41 Sponsor Protocol Number: RPL554-009-2015 Start Date*: 2015-09-18
    Sponsor Name:Verona Pharma plc
    Full Title: A phase II, randomised, double blind, placebo controlled, six way crossover study to assess the bronchodilator effect of RPL554 administered on top of salbutamol and ipratropium in patients with COPD
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002283-27 Sponsor Protocol Number: 1812VA323 Start Date*: 2020-03-18
    Sponsor Name:Shionogi B.V.
    Full Title: A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose selection study of S-600918 in patients with refractory chronic cough
    Medical condition: Refractory chronic cough
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10066656 Chronic cough LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003107-29 Sponsor Protocol Number: N°005 Start Date*: 2015-08-07
    Sponsor Name:GALMED Pharmaceuticals LTD.
    Full Title: A Phase IIb, double blind, randomized controlled clinical trial to evaluate the efficacy and safety of two Aramchol doses versus placebo in patients with Non-Alcoholic- Steatohepatitis (NASH).
    Medical condition: Non-alcoholic Steatohepatitis in patients with two additional features of metabolic syndrome -overweight or obesity and Diabetes Mellitus type II or pre-diabetes.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) RO (Ongoing) LT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004869-27 Sponsor Protocol Number: MK-3475-756 Start Date*: 2019-05-03
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Es...
    Medical condition: High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004273-10 Sponsor Protocol Number: 3200L2-300-WW Start Date*: 2007-01-08
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of intravenous Methylnaltrexone (MOA-728) for the treatment of post operative ileus
    Medical condition: Post operative ileus (POI) in patients who have had a segmental colectomy via open laparotomy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-000905-38 Sponsor Protocol Number: PCYC-1137-CA Start Date*: 2015-12-17
    Sponsor Name:Pharmacyclics LLC
    Full Title: A randomized, multicenter, double-blind, placebo-controlled, Phase 3 study of the Bruton’s Tyrosine Kinase inhibitor ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in c...
    Medical condition: metastatic pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001804-22 Sponsor Protocol Number: PGL07-021 Start Date*: 2008-10-16
    Sponsor Name:PregLem S.A.
    Full Title: A Phase III, randomized, parallel group, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus placebo for pre-operative treatment of...
    Medical condition: Uterine myoma are benign, monoclonal, hormone sensitive, smooth muscle tumors of the uterus. It is the most common tumor of the female reproductive tract in pre-menopausal women and mostly asympto...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046801 Uterine myoma LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004269-96 Sponsor Protocol Number: IG8801CLBP201 Start Date*: 2016-02-24
    Sponsor Name:Gador S.A.
    Full Title: A 24 weeks multicentre, randomized, double-blind, placebo-controlled, parallel group, study to evaluate the efficacy, safety and tolerability of intravenous IG-8801 20 mg and 40 mg in subjects with...
    Medical condition: non-specific Chronic Low Back Pain persisting for at least 3 months
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10008837 Chronic back pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004559-29 Sponsor Protocol Number: M10-447 Start Date*: 2014-11-12
    Sponsor Name:AbbVie Inc.
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-controlled Study of Adalimumab in Japanese Subjects with Moderately to Severely Active Ulcerative Colitis
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000197-35 Sponsor Protocol Number: IR-HP-14-01 Start Date*: 2015-06-09
    Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI
    Full Title: insulin resistance, obesity and gastrointestinal bacteria
    Medical condition: Helicobacter pylori infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10022489 Insulin resistance PT
    18.1 100000004862 10004028 Bacterial infection due to helicobacter pylori (H. pylori) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003370-26 Sponsor Protocol Number: CLAF237ADE03 Start Date*: 2007-11-15
    Sponsor Name:Charite Universitätsmedizin Berlin
    Full Title: A prospective, single center, double blind, placebo controlled study of adipocytokines, adipose tissue gene expression and hepatic insulin clearance in the therapeutic response to vildagliptin in man
    Medical condition: This is a single center, randomized, double-blind pilot study on patients with Type 2 diabetes. The purpose of this study is to test the effects of vildagliptin (as add-on to metformin) on hepatic ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003439-53 Sponsor Protocol Number: TMC353121-TiDP19-C202 Start Date*: 2006-12-08
    Sponsor Name:Tibotec Pharmaceuticals Ltd
    Full Title: A double blind, randomized, placebo-controlled study to evaluate the antiviral activity, safety and plasma pharmacokinetics of multiple intravenous doses of TMC353121 in hematopoietic stem cell tra...
    Medical condition: Respiratory Synctycial Virus (RSV)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010901-35 Sponsor Protocol Number: G83627057 Start Date*: 2010-04-14
    Sponsor Name:Fundación de Investigación Biomédica Hospital La Paz
    Full Title: ESTUDIO ALEATORIZADO Y DOBLE CIEGO CON DOBUTAMINA VERSUS PLACEBO PARA EL TRATAMIENTO DEL BAJO FLUJO EN VENA CAVA SUPERIOR EN RECIÉN NACIDOS DE BAJO PESO: EVALUACIÓN SISTEMÁTICA DE LOS EFECTOS SOBRE...
    Medical condition: BAJO FLUJO EN VENA CAVA SUPERIOR
    Disease: Version SOC Term Classification Code Term Level
    9 10007539 Cardiac disorder signs and symptoms HLGT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001851-29 Sponsor Protocol Number: BAY2253651/19038 Start Date*: 2018-07-25
    Sponsor Name:Bayer AG
    Full Title: Randomized, multi-center, double-blind, placebo-controlled, group-comparison study to investigate safety, tolerability and pharmacodynamics of BAY2253651 after administration of a single nasal dose...
    Medical condition: Obstructive sleep Apnea
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002283-41 Sponsor Protocol Number: 151032-002 Start Date*: 2017-09-11
    Sponsor Name:HRA Pharma
    Full Title: A prospective, randomized, parallel-group study to assess the effects on ovarian activity of ellaOne (ulipristal acetate 30 mg single dose) taken after three consecutive days of missed combined ora...
    Medical condition: Emergency contraception
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001946-93 Sponsor Protocol Number: NalGamb Start Date*: 2017-10-31
    Sponsor Name:National Instute of Health and Welfare
    Full Title: Double-blind, placebo-controlled randomised study on the efficacy of naloxone nasal spray for the treatment of gambling disorder
    Medical condition: Problem gambling
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000167845 10017657 Gambling pathological LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2012-002699-14 Sponsor Protocol Number: DPM-CF-204 Start Date*: 2013-01-28
    Sponsor Name:Pharmaxis Ltd.
    Full Title: A randomised, multicentre, double-blind, placebo-controlled, crossover trial determining the efficacy of dry powder mannitol in improving lung function in subjects with Cystic Fibrosis aged six to ...
    Medical condition: Cystic fibrosis in children aged 6 to 17 years
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) BE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 63  64  65  66  67  68  69  70  71  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Feb 13 05:07:09 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA